fashion -WSS

fashion

author：explore 2025-09-14 18:30:20 - browse：61756

What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We explain the debate over Vertex Pharmaceuticals’ novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.

For more on what we cover, here’s the news on Vertex; here’s more on Aduhelm; here’s the exit interview with Janet Woodcock; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Explaining an after

Wikipedia

WSS

Inari Medical to buy amputation prevention company LimFlow

Medicare proceeds with plan to claw back hospital funds

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

The health care issue Democrats can’t solve: hospital reform

Life sciences deals on track to hit lowest point since 2017

Readout LOUD podcast: Merger Mondays, Ozempic panic

knowledge

fashion

hotspot

Supreme Court strikes down use of affirmative action

How neuroscience research could help beat back brain cancer

United colonoscopy coverage change 'may cost lives,' doctors say

Lung cancer screening guidelines updated for cigarette smokers

Affirmative action in medical school literally saved lives

Inari Medical to buy amputation prevention company LimFlow

State Dept. review finds Biden bears some blame for Afghanistan failures

Key Senate panel to consider PBM, drug pricing reform package

ChatGPT in medicine: STAT answers readers' burning questions

Coloradans with cystic fibrosis could lose access to Trikafta

focus

Key Senate panel to consider PBM, drug pricing reform package

Life sciences investors close nearly $6 billion in new funds

Brain injuries and the importance of a second opinion

European regulators recommend Amylyx's ALS drug be rejected

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Akero's treatment for NASH falls short in cirrhosis study

hotspot

Wikipedia

knowledge

hotspot